Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATTERN: Paclitaxel + Carboplatin vs FEC-Docetaxel in TNBC
NCT04031703Phase 3
Key facts
- Status
- Completed
- Start
- Jan 2011
- Primary completion
- Apr 2016
- Sponsor
- Fudan University
- Modality
- DNA Intercalators/Alkylators
- Conditions
- triple negative breast cancer (TNBC)
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in triple negative breast cancer (TNBC), sponsored by Fudan University. Started Jan 2011; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Women aged 18-65 with localized invasive triple-negative breast cancer (ER-/PR-/HER2-) after surgery, with positive lymph nodes or high-risk negative lymph nodes.
04
Registry description
This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer
Beyond the preview
Go deeper on NCT04031703.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031703.